Changes in serotype prevalence and antimicrobial resistance among invasive Streptococcus pneumoniae isolates in Korea, 1996Korea, -2008 We investigated changes in serotypes and antimicrobial susceptibilities among 386 isolates of invasive Streptococcus pneumoniae collected from numerous hospitals in Korea from 1996 to 2008. Serotypes 19F (9.8 %), 23F (8.3 %), 19A (7.8 %), 6A (7.5 %), 3 (7.3 %), 9V (6.5 %), 6B (6.2 %), 14 (4.9 %), 1 (3.9 %), 11A (3.9 %) and 4 (3.1 %) represented 69.2 % of all isolates. While the overall proportion of PCV7 serotypes was stable over time, we observed modest decreases in children ,5 years old and in adults ¢65 years old between 1996-1999 and 2007-2008. An increased prevalence of non-PCV7 serotypes in these age groups was primarily attributable to an increase in serotypes 3, 6A and 19A. Most invasive S. pneumoniae isolates showed high resistance rates to erythromycin (74.9 %), tetracycline (71.1 %) and clindamycin (61.7 %). Between 1996Between -2003Between and 2004Between -2008, non-susceptibility rates to cefotaxime and multi-drugs (three or more classes) in PCV7 serotypes showed a declining trend, while in non-PCV7 serotypes there was an increasing trend. Non-PCV7 serotypes 6A and 19A, which mostly exhibited multidrug-resistant phenotypes (69.0 % and 76.7 % respectively), increased between
INTRODUCTION
Invasive pneumococcal diseases (IPDs), such as bacteraemia and meningitis, continue to pose a significant risk to children ,2 years old and adults ¢65 years old (Chen et al., 2006) . The 23-valent pneumococcal polysaccharide vaccine (PPV23) and the 7-valent pneumococcal conjugate vaccine (PCV7) have been successful in reducing the burden of IPDs in high-risk groups. The USA and several countries in Europe have adopted PCV7 into their national immunization programmes for all children, and a decline in IPDs has been reported (Stephens et al., 2005; Talbot et al., 2004; Whitney et al., 2003) . The prevalence of serotypes causing IPDs varies over time and geographically (Hausdorff et al., 2005) . The increased use of PCV7 has led to epidemiological changes; in particular there has been an increase of non-vaccine serotypes, not covered by PCV7, in invasive and non-invasive pneumococcal diseases in many countries (Hicks et al., 2007; Pai et al., 2005; Pichichero & Casey, 2007) . Changing pneumococcal serotype distributions necessitates a strengthened IPD surveillance system designed to estimate the potential effect of pneumococcal vaccines in each region.
The high prevalence of penicillin-, erythromycin-and multidrug-resistant (MDR) S. pneumoniae has become a driving factor of vaccine use for protection against pneumococcal diseases (Whitney et al., 2003) . Korea has a high rate of MDR pneumococci. PPV23 and PCV7 vaccines were introduced in Korea in 1993 and 2003, respectively. The latter is gradually being replaced by the 10-and 13-valent pneumococcal conjugate vaccines since they were approved and introduced in Korea in 2010. However, pneumococcal vaccines have not yet been fully routinely implemented in the national immunization programme and the direct effect of these vaccines on the incidence and serotype distribution of IPDs in Korea remains unclear.
Despite the importance of IPDs serotype data in guiding pneumococcal immunization strategies, little is known of the prevalence of serotypes causing IPDs in Korea. According to a recent report from one Korean tertiary-care hospital, serotype 19A increased among children (,5 years old) from 0 % in 1996 to 26 % in 2003, before the introduction of PCV7 (Choi et al., 2008) . This situation differs from the USA, where the increased frequency of replacement serotype 19A has occurred in response to the widespread use of PCV7 (Dagan & Klugman, 2008; Hicks et al., 2007) .
In this study, we describe changes in serotype prevalence and antimicrobial susceptibility of invasive S. pneumoniae strains before and after introduction of PCV7, to inform future vaccine strategies in Korea.
METHODS
Bacterial strains. All S. pneumoniae strains were isolated from patients with IPDs at ten secondary and tertiary hospitals and two clinical diagnostic centres in Korea from 1996 to 2008. Invasive isolates were defined as strains from normally sterile body sites [blood, cerebrospinal fluid (CSF), pleural fluid and ascitic fluid] from outpatients and inpatients of all ages with IPD. All isolates were transported to the Division of Bacterial Respiratory Infections, Korea Centers for Disease Control, where each isolate was subcultured, identified by conventional standard procedures and stored at 270 uC.
Serotyping. S. pneumoniae strains were serotyped by capsular swelling (quellung reaction) with pool and serotype/group-specific antisera provided by Statens Serum Institute (Copenhagen, Denmark). Due to the recently recognized serotype 6C cross-reacting serologically with serotype 6A (Jacobs et al., 2009) , all apparent serotype 6A strains were differentiated by a serotype 6C-specific PCR (Park et al., 2007) .
Antimicrobial susceptibility. MICs were determined using the broth microdilution method with Mueller-Hinton broth supplemented with 3 % lysed horse blood, according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI, 2008) . The following antimicrobial agents were tested: penicillin G, cefotaxime, erythromycin, clindamycin, tetracycline, sparfloxacin, levofloxacin and vancomycin (all from Sigma). S. pneumoniae ATCC 49619 was used as a control strain. The proportions of susceptible, intermediate and resistant isolates to each agent were determined based on the breakpoints recommended by CLSI (2008) . For penicillin, meningitis non-susceptibility was MIC ¢0.12 mg ml 21 and non-meningitis nonsusceptibility was MIC ¢4 mg ml 21 . For cefotaxime, meningitis nonsusceptibility was MIC ¢1 mg ml 21 and non-meningitis nonsusceptibility was MIC ¢2 mg ml 21 .
Statistical analysis. Statistical analysis for comparison of serotype and antimicrobial susceptibility changes was performed using SAS software version 9.2 (SAS Institute). A P-value ,0.05 was considered significant.
RESULTS AND DISCUSSION
Collection of S. pneumoniae isolates A total of 386 S. pneumoniae strains were isolated during the period. Of 386 patients, 250 (64.8 %) were male and 129 (33.4 %) were female. For seven, the sex was not stated.
The mean age of the patients was 43.7±28.1 years (range 0-99 years). Most of the S. pneumoniae isolates were obtained from adults. Of all isolates, 116 (30.1 %) were obtained from the elderly ¢65 years old and 74 (19.2 %) from children ,5 years old. The commonest specimen was blood (n5351, 90.9 %), followed by CSF (n513, 3.4 %), pleural fluid (n512, 3.1 %) and ascitic fluid (n52, 0.5 %). Five strains (1.3 %) were isolated from both blood and CSF, and three strains (0.8 %) were isolated from both blood and pleural fluid of the same patient. These duplicate isolates were considered as one isolate in the case of the same serotype.
Serotype prevalence
The most frequent serotypes were 19F, 23F, 19A, 6A, 3, 9V, 6B, 14, 1 and 11A, accounting for 69.2 % of all isolates (Table 1) . No serotype 6C strains were detected. In children ,5 years old, 18 serotypes were identified and the major serotypes were 23F, 14, 19A, 6A and 19F. In elderly patients (¢65 years old), the diversity of serotypes was higher than in children with 33 serotypes identified; serotypes 3, 19F and 11A were prevalent. PCV7 serotype coverage was 59.5 % in children ,5 years old, and the newly introduced 10-valent and 13-valent vaccines were expected to cover 62.2 % and 86.4 % in this group, respectively. In the case of PPV23, serotype coverage was 77.2 % of all ages and 80.2 % in the elderly. If the 13-valent vaccine for adults is approved and introduced, it would provide coverage of 67.2 % of serotypes in the elderly. The change in proportions of serotypes over time is shown in Table 2 . The analysis was categorized into four periods based on the introduction of PCV7 in Korea (two 4-year periods prevaccine then two periods post-vaccine, 3 years and 2 years, respectively): 1996-1999, n584 strains; 2000-2003, n585 strains; 2004-2006, n5107 strains; and 2007-2008, n5110 strains. For all ages, the proportion of serotypes covered with PCV7 vaccine showed no significant difference over time (Table 2) . Serotype 19F had a consistently high prevalence over these four periods. In children ,5 years old, the proportion of PCV7 serotypes declined from 69.2 % in 1996-1999 to 50.0 % in [2007] [2008] . The proportion of non-PCV7 serotypes showed an increasing trend after PCV7 introduction, especially in children ,5 years old and the elderly. There appeared to be an increasing trend in serotype 6A and 19A, but numbers were small. Serotype 3 increased progressively in the elderly from 0.0 % in 1996-1999 to 22.9 % in 2007-2008 (P,0.02) .
Antimicrobial resistance
Antimicrobial non-susceptibilities for seven antimicrobial agents tested are shown in Table 3 . The highest resistance overall was observed for erythromycin (74.9 %), tetracycline (71.1 %) and clindamycin (61.7 %), while 31.1 % and 10.4 % of isolates were non-susceptible to cefotaxime and penicillin, respectively. Resistance to these five antimicrobial agents was higher in children ,5 years old compared to adults ¢65 years old, especially non-susceptibility to penicillin and cefotaxime, which was 2.7-fold (P,0.02) and 1.9-fold (P,0.01) higher, respectively. Most (60.4 %) IPD serotypes were MDR.
Antimicrobial resistance and serotypes PCV7 serotypes were more resistant to most antimicrobial agents tested than non-PCV7 isolates both pre-and postvaccine introduction (Table 4 ). The MDR rate of PCV7 serotypes (76.6 %) was higher than that of non-PCV7 serotypes (49.1 %). PCV7 serotypes showed a declining trend in resistance between 1996-2003 and 2004-2008 , especially cefotaxime non-susceptibility (29.3 %) and multidrug resistance (211.0 %). In contrast, non-PCV7 serotypes showed increased non-susceptibility to cefotaxime (+9.5 %) and multidrug resistance (+15.6 %: P,0.02). Most of the non-PCV7 serotype 6A (69.0 %) and 19A (76.7 %) were MDR strains. The MDR rates of serotype 6A and 19A increased (+32.4 % and +16.6 %, respectively) from 1996-2003 to 2004-2008 (combined increase 24.5 %, P,0.05). Interestingly, non-PCV7 serotypes showed a significant decline in erythromycin resistance (230.0 %; P,0.01) over this time (Table 4) .
This study describes the prevalence of serotypes and antimicrobial susceptibilities among invasive S. pneumoniae isolates collected from multiple hospitals in Korea over a 13-year-period from 1996 to 2008. The proportion , 1996-1999; P2, 2000-2003; P3, 2004-2006; P4, 2007-2008 Many developed countries have adopted PCV7 into their national child immunization programmes, and its effectiveness has been reported in vaccinated children and unvaccinated adults (Dagan & Klugman, 2008; Dagan, 2009; Hicks et al., 2007; van Gils et al., 2010) . In Korea, PCV7 was introduced in November 2003 as part of an optional immunization programme available at private clinics and its impact on the serotype distribution of invasive S. pneumoniae is not so clear.
PCV7 serotypes 19F, 23F, 9V, 6B and 14 remain prevalent in association with invasive disease in Korea, presumably due to low vaccination coverage. It may be that PCV7 vaccination produced a direct effect in vaccinated children, evidenced by a modest decrease in IPD associated with PCV7 types in children ,5 years old, but vaccination coverage was not high enough to cause a herd effect to prevent IPDs in unvaccinated adults in Korea.
Our findings are similar to those of previous reports in children ¡5 years old in Korea (Choi et al., 2008) , but there were some differences. The proportion of serotype 3 among adults was considerably higher than that among children in this study. This lower prevalence of serotype 3 in children is in accordance with our previous report , where serotype 3 was the fifth most prevalent serotype in adults with non-invasive pneumococcal disease from 2002 to 2005, but was not observed in children. This agrees with the increase of serotype 3 in adults with pneumonia and IPD in Japan and Taiwan, geographically close to Korea (Chen et al., 2006; Isozumi et al., 2008) . However, conflicting results have been reported whereby serotype 3 was associated with IPD in all age groups and was most frequent among infected neonates (Imöhl et al., 2010) . DP1-P2, 1996 DP1-P2, -2003 DP1-P2, (pre-vaccination era). dP3-P4, 2004 DP1-P2, -2008 . §N-PCV7, Non-PCV7 serotypes. The increase of IPD caused by non-PCV7 serotypes is a major concern in many countries that have implemented PCV7 vaccination (Dagan, 2009; Eun et al., 2010; Lee et al., 2010; Talbot et al., 2004 ). An increase of IPD serotype 19A and 6C and a reduction in serotype 6A has been reported following introduction of PCV7 vaccination (Dagan & Klugman, 2008; Dagan, 2009; Jacobs et al., 2009) . In contrast to other studies, we observed a high prevalence of serotype 6A among children and adults and no serotype 6C.
Generally, one of the beneficial outcomes of PCV7 vaccination is the reduction of drug-resistant S. pneumoniae. This benefit influences PCV7 serotypes, but not non-PCV7 serotype (Dagan & Klugman, 2008) . As expected, we observed a decline in drug resistance (except penicillin) among the PCV7 serotypes and, among non-PCV7, an increase in drug resistance (except erythromycin) between 1996-2003 and 2004-2008 . Nevertheless, most IPD serotypes had clinically significant drug resistance including a high MDR rate (60.4 %). The resistance rate of cefotaxime was higher than that of respiratory tract isolates reported previously . The MDR rate of PCV7 serotypes was higher than that of non-PCV7 serotypes. However, the MDR rate of PCV7 serotypes decreased while that of non-PCV7 serotypes increased after PCV7 introduction. This high prevalence of MDR phenotypes in invasive S. pneumoniae continues to be an important clinical problem in our community.
Most notable was an increase of drug resistance in non-PCV7 serotypes 6A and 19A. Many epidemiological studies have reported a significant increase in the incidence of IPD caused by serotype 19A, which has an MDR phenotype, in all age groups after PCV7 introduction or even without vaccination (Choi et al., 2008; Dagan, 2009; Hicks et al., 2007; Jefferies et al., 2010; Pai et al., 2005; Pichichero & Casey, 2007; van Gils et al., 2010) . With the lower rate of PCV7 vaccination in children in our community, the stillhigh prescription rate of antimicrobial drugs may provide selective pressure that would drive the emergence of MDR strains of non-PCV7 serotype 6A and 19A and their selective advantage over other strains. Although contentious, the increase of serotype 19A was shown to be involved in the expansion of the pre-existing MDR ST320 clone before PCV7 use in Korea (Choi et al., 2008) . A recent study suggested that the emergence of MDR 19A is attributable to driving forces such as PCV7 vaccine selection pressure, antibiotic selection pressure, and pneumococcal mutation events (Pillai et al., 2009) . To reduce the rapid expansion of MDR strains in non-vaccine serotypes, further efforts should be directed to the use of expanded-spectrum vaccines and the reduction of extensive antibiotic prescriptions.
We have examined the change of serotype distribution and antimicrobial susceptibility of IPD isolates in Korea over 13 years. This study has limitations for accurate analysis of the relationship between serotype distribution and vaccine effect because there is no national IPD surveillance system and pneumococcal vaccination is not yet universal. Nevertheless, this study provides details of serotype occurrence, which will be useful when considering pneumococcal vaccination strategies in Korea. S. pneumoniae serotypes have emerged and disappeared within short periods under the influence of several factors. Reliable molecular surveillance is needed to track changing serotypes and drug resistance in S. pneumoniae and assess an effect of pneumococcal vaccine in Korea.
